AI/ML Innovations Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- AI/ML Innovations Inc. is a Canada-based global technology company specializing in artificial intelligence (AI) and machine learning (ML) applications, primarily targeting the digital healthcare sector. Founded in 2009 and headquartered in Victoria, British Columbia, the company develops proprietary platforms that convert complex biometric data into actionable clinical insights to support earlier diagnosis, personalized treatment, and improved healthcare outcomes. Its core product offerings include AI-driven digital health solutions; patented neural network technology; smart sensor wearables and biometric data analysis tools marketed through its majority-owned subsidiary Health Gauge Inc.; and a growing portfolio of AI/ML-powered healthcare software applications accessible via the commercial portal Neural Net Store. The company also holds strategic investments and majority stakes in emerging digital health companies such as Tech2Heal, AI Rx Inc., and NeuralCloud Solutions Inc. Recent major developments include the December 2024 acquisition of Quantum Sciences Ltd., which expands AI/ML Innovations’ capabilities into cardio AI-driven healthcare technologies addressing cardiovascular, neurodegenerative, and metabolic diseases; the launch of Health Gauge's innovative “Pulse Whisperer” product suite for biometric raw signal data aimed at life sciences researchers; and the completion of technology acquisitions from Naiad Lab Inc. These strategic moves strengthen the company's position in AI-based personalized medicine and digital health management globally, leveraging AI, ML, cloud computing, and data analytics to transform healthcare delivery across multiple markets.
Company News
AI/ML Innovations Announces Completion of Share Issuance
AI/ML Innovations Appoints Lynn Chapman as Chief Financial Officer and Announces Share Issuance for Debt Settlement
AIML Subsidiary NeuralCloud Signs Binding Commercial Term Sheet with VetMed Consultants for MaxYield(TM) ECG Services
AIML Subsidiary NeuralCloud Enters Strategic Partnership with RKS Medical Technologies to Advance CardioYield(TM) Clinical Pilots
AI/ML Innovations Launches Quantum Soma Initiative with Dynex Quantum Technologies for Contactless Quantum Biosensing Platform
AI/ML Innovations Inc. Closes Final Tranche of Private Placement
AI/ML Innovations subsidiary NeuralCloud Appoints Former FDA Reviewer Dr. Mehmet Kosoglu as the Head of Regulatory Affairs
AI/ML Innovations Inc. Closes First Tranche of Private Placement
AIML Subsidiary NeuralCloud Signs Term Sheet with Island Mobile Cardiology Testing for CardioYield(TM) Pilot
AI/ML Innovations Inc. Announces Proposed Private Placement
AI/ML Innovations' Subsidiary NeuralCloud Achieves ISO 13485:2016 (MDSAP) Certification
AI/ML Innovations Announces Completion of Share Issuance
AI/ML Subsidiary NeuralCloud Appoints Cardiac Monitoring Veterans Dale and Nicholas DuBois to Lead Clinical and Overread Operations
AI/ML Innovations Inc. Announces Closing of Final Tranche of Private Placement to Raise $1,917,500
AIML Appoints Dr. Martin Green to Medical Advisory Board and Issue Options
AI/ML Innovations Announces Completion of Share Issuance
AI/ML Innovations Announces Completion of Share Issuance
Neural Cloud Signs Reseller Agreement with European Digital Cardiac Monitoring Platform
AI/ML Innovations Inc. Announces Closing of First Tranche of Private Placement to Raise $950,000
AIML Subsidiary NeuralCloud Enters Research Services Agreement with Baker Heart and Diabetes Institute to Support AI-Driven ECG Analysis